Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 15/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.31 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.31 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25320149 | 1.00 | TIPARP (0.45) | TIPARPDGAT1PARP1CYP2C9PARP14 | |
| SCHEMBL30550644 | 1.00 | TIPARP (0.45) | TIPARPDGAT1PARP1CYP2C9PARP14 | |
| SCHEMBL25321245 | 0.92 | TIPARP (0.41) | TIPARPDGAT1GRM2 | |
| SCHEMBL30550711 | 0.92 | TIPARP (0.41) | TIPARPDGAT1GRM2 | |
| SCHEMBL30550713 | 0.92 | TIPARP (0.41) | TIPARPDGAT1GRM2 | |
| SCHEMBL25321909 | 0.89 | TIPARP (0.36) | TIPARPDGAT1PARP1CYP2C9PARP14 | |
| SCHEMBL31362881 | 0.89 | TIPARP (0.34) | TIPARP | |
| SCHEMBL30550610 | 0.89 | TIPARP (0.36) | TIPARPDGAT1PARP1CYP2C9PARP14 | |
| SCHEMBL25321896 | 0.89 | TIPARP (0.36) | TIPARPDGAT1PARP1CYP2C9PARP14 | |
| SCHEMBL31058417 | 0.86 | TIPARP (0.41) | TIPARPDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | TIPARP 491/4885DGAT1 2812/4885PARP1 1/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | TIPARP 491/4885DGAT1 2812/4885PARP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.